Related Experiment Videos
Survivin expression in chronic myeloid leukemia.
Enrico Conte1, Fabio Stagno, Patrizia Guglielmo
1Department of Biomedical Sciences, Pathology Section, University of Catania, via Androne 83, Catania I-95124, Italy. econte@unict.it
Cancer Letters
|June 1, 2005
Summary
Survivin (SVV) is highly expressed in chronic myeloid leukemia (CML) patients, increasing with disease progression. SVV monitoring may aid CML diagnosis and targeted therapy development.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome.
- Survivin (SVV) is an inhibitor of apoptosis protein implicated in cancer progression.
Purpose of the Study:
- To investigate survivin (SVV) expression in chronic myeloid leukemia (CML) patients.
- To correlate SVV levels with CML phases and disease markers.
Main Methods:
- Expression analysis of survivin (SVV) in 44 CML patients and 20 healthy donors.
- Comparison of SVV levels across different CML phases (chronic, accelerated/blastic).
- Correlation analysis of SVV expression with Ph-chromosome percentage, Bcr-Abl levels, and WBC count.
Main Results:
- High survivin (SVV) expression was detected in a majority of CML patients.
- Significantly elevated SVV levels were observed in accelerated/blastic phase CML compared to chronic phase.
- SVV expression correlated positively with Ph-chromosome percentage, Bcr-Abl levels, and WBC count in CML patients.
Conclusions:
- Survivin (SVV) is a potential biomarker in chronic myeloid leukemia (CML).
- SVV detection and monitoring could inform targeted and combined therapeutic strategies for CML.